Compare Entegris Inc (ENTG) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Immunovant Inc. Common Stock — how do they compare? Entegris Inc trades at $165.04 (market cap $25.41B), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: Entegris Inc is far larger — about 3.8× Immunovant Inc. Common Stock's market cap, and Entegris Inc pays a 0.24% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Immunovant Inc. Common Stock for 0 Days on average.
| ENTG | IMVT | |
|---|---|---|
Market Cap | $25.41B | $6.62B |
Volume | 2,160,232 | 1,131,364 |
Sector | Technology | Health |
52-Week High | $184.00 | $44.96 |
52-Week Low | $68.80 | $17.03 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $28.62B | $5.72B |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $162.19, down 2.82% today, with strong technical momentum as moving averages signal bullish alignment. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $0.93 versus $0.82, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B in 2025, while net income margin improved to 9.18% in 2026 projections. Recent institutional buying includes BlackRock's $3.68 billion position, reflecting confidence in Entegris' advanced materials leadership.
Outlook remains positive with analyst consensus target of $182.43 suggesting 12.5% upside, supported by 70% buy ratings. Key risks include high valuation multiples (P/E 83.16) and semiconductor cycle sensitivity. The upcoming Q3 earnings on October 29, 2026, and Investor Day on November 9, 2026, are critical catalysts for confirming growth trajectory amid competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
